NASDAQ:VVUS - Vivus Stock Price, Price Target & More

$0.3851 -0.02 (-4.94 %)

(As of 04/22/2018 04:12 AM ET)

Previous Close$0.3851

Today's Range$0.3851 - $0.4227

52-Week Range$0.33 - $1.38

Volume276,681 shs

Average Volume419,966 shs

Market Capitalization$42.51 million

P/E Ratio-1.33

Dividend YieldN/A

Beta0.61

About Vivus (NASDAQ:VVUS)

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:VVUS

CUSIP92855110

Webwww.vivus.com

Phone650-934-5200

Debt

Debt-to-Equity Ratio-24.71%

Current Ratio6.80%

Quick Ratio6.34%

Price-To-Earnings

Trailing P/E Ratio-1.33

Forward P/E Ratio-0.86

P/E GrowthN/A

Sales & Book Value

Annual Sales$65.37 million

Price / Sales0.62

Cash FlowN/A

Price / CashN/A

Book Value($0.09) per share

Price / Book-4.28

Profitability

EPS (Most Recent Fiscal Year)($0.29)

Net Income$-30,510,000.00

Net Margins-46.67%

Return on Equity-843.43%

Return on Assets-10.99%

Miscellaneous

Employees52

Outstanding Shares106,020,000

How to Become a New Pot Stock Millionaire

Vivus (NASDAQ:VVUS) Frequently Asked Questions

What is Vivus' stock symbol?

Vivus trades on the NASDAQ under the ticker symbol "VVUS."

How were Vivus' earnings last quarter?

Vivus (NASDAQ:VVUS) announced its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. The biopharmaceutical company earned $11.94 million during the quarter. Vivus had a negative return on equity of 843.43% and a negative net margin of 46.67%. View Vivus' Earnings History.

When is Vivus' next earnings date?

Vivus is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Vivus.

Who are some of Vivus' key competitors?

Some companies that are related to Vivus include Gemphire Therapeutics (GEMP), Medicure (MCUJF), Novelion Therapeutics (NVLN), Cardiome Pharma (CRME), Novan (NOVN), MEI Pharma (MEIP), Alimera Sciences (ALIM), Xenon Pharmaceuticals (XENE), Eleven Biotherapeutics (EBIO), vTv Therapeutics (VTVT), Regulus Therapeutics (RGLS), Vascular Biogenics (VBLT), Sophiris Bio (SPHS), Axsome Therapeutics (AXSM), Arcturus Therapeutics (ARCT), Scynexis (SCYX), Vernalis (VNLPY) and Versartis (VSAR).

Who are Vivus' key executives?

Vivus' management team includes the folowing people:

Mr. Mark K. Oki, CFO & Chief Accounting Officer (Age 49)
Mr. John L. Slebir Esq., Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 53)
Dr. Santosh T. Varghese M.D., Chief Medical Officer (Age 48)
Mr. Seth H. Z. Fischer, Strategic Adviser (Age 62)
Mr. Thomas B. King, Interim CEO & Director (Age 63)

Has Vivus been receiving favorable news coverage?

Media headlines about VVUS stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vivus earned a news impact score of 0.07 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Vivus?

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vivus' stock price today?

One share of VVUS stock can currently be purchased for approximately $0.3851.

How big of a company is Vivus?

Vivus has a market capitalization of $42.51 million and generates $65.37 million in revenue each year. The biopharmaceutical company earns $-30,510,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Vivus employs 52 workers across the globe.

How can I contact Vivus?

Vivus' mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]

MarketBeat Community Rating for Vivus (VVUS)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		250 (Vote Outperform)
Underperform Votes:		304 (Vote Underperform)
Total Votes:		554

MarketBeat's community ratings are surveys of what our community members think about Vivus and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Vivus (NASDAQ:VVUS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	N/A	N/A	N/A	N/A
Consensus Rating Score:	N/A	N/A	N/A	N/A
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Vivus (NASDAQ:VVUS) Consensus Price Target History

Price Target History for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ:VVUS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
7/25/2016	WallachBeth Capital	Set Price Target	Buy	$2.80	N/A
5/4/2016	JPMorgan Chase	Reiterated Rating	Hold		N/A

(Data available from 4/22/2016 forward)

Vivus (NASDAQ:VVUS) Earnings History and Estimates Chart

Earnings by Quarter for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ:VVUS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Vivus (NASDAQ VVUS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		($0.11)					N/A
3/13/2018	Q4 2017	($0.13)	($0.0950)		$11.94 million	View	N/A
11/7/2017	Q3 2017	($0.13)	($0.0570)	$16.00 million	$15.19 million	View	N/A
8/3/2017	Q2 2017	($0.13)	($0.13)		$11.23 million	View	N/A
5/3/2017	Q1 2017	($0.13)	($0.01)		$27.01 million	View	Listen
3/8/2017	Q4 2016	$0.23	$0.54	$48.82 million	$81.81 million	View	Listen
11/9/2016	Q316	($0.19)	($0.09)	$21.91 million	$13.40 million	View	Listen
8/4/2016	Q216	($0.31)	($0.11)	$19.00 million	$13.77 million	View	N/A
5/3/2016	Q116	($0.21)	($0.12)	$17.97 million	$15.32 million	View	N/A
3/9/2016	Q4	($0.12)	($0.12)	$22.90 million	$15.34 million	View	N/A
11/4/2015	Q315	($0.17)	($0.15)	$20.24 million	$24.90 million	View	N/A
7/30/2015	Q215	($0.23)	($0.19)	$18.76 million	$23.00 million	View	Listen
5/5/2015	Q115	($0.22)	($0.15)	$21.80 million	$32.20 million	View	N/A
2/24/2015	Q414	($0.25)	($0.25)	$20.00 million	$21.70 million	View	Listen
11/5/2014	Q314	($0.25)	($0.10)	$21.90 million	$33.90 million	View	Listen
8/7/2014	Q214	($0.28)	($0.25)	$17.90 million	$21.90 million	View	Listen
5/5/2014	Q114	($0.37)	($0.15)	$11.40 million	$36.70 million	View	N/A
2/24/2014	Q413	($0.40)	($0.17)	$28.20 million	$44.06 million	View	Listen
11/5/2013	Q313	($0.38)	($0.48)	$21.78 million	$27.38 million	View	N/A
8/6/2013	Q2 2013	($0.44)	($0.55)	$12.76 million	$5.53 million	View	N/A
5/8/2013	Q1 2013	($0.51)	($0.53)	$5.22 million	$4.10 million	View	N/A
2/25/2013	Q4 2012	($0.44)	($0.56)	$3.09 million	$1.97 million	View	N/A
11/6/2012	Q312	($0.34)	($0.40)	$0.35 million	$0.04 million	View	N/A
8/7/2012		($0.23)	($0.24)			View	N/A
5/7/2012		($0.13)	($0.20)			View	N/A
2/28/2012		($0.12)	($0.14)			View	N/A
11/7/2011		($0.12)	($0.10)			View	N/A
8/1/2011		($0.13)	($0.20)			View	N/A
5/2/2011		($0.15)	($0.12)			View	N/A
2/28/2011		($0.22)	($0.23)			View	N/A
11/8/2010	Q3 2010	($0.27)	($0.22)			View	N/A
8/2/2010	Q2 2010	($0.23)	($0.28)			View	N/A
5/3/2010	Q1 2010	($0.26)	($0.23)			View	N/A
3/8/2010	Q4 2009	($0.25)	($0.16)			View	N/A
11/3/2009	Q3 2009	($0.31)	($0.30)			View	N/A
8/11/2009	Q2 2009	($0.18)	($0.19)			View	N/A
5/11/2009	Q1 2009	($0.08)	($0.10)			View	N/A
3/9/2009	Q4 2008		($0.05)			View	N/A
8/4/2008	Q2 2008	($0.05)	$0.06			View	N/A
5/8/2008	Q1 2008	$0.08	($0.12)			View	N/A
3/6/2008	Q4 2007	$0.21	$0.17			View	N/A

(Earnings results data provided by Zacks Investment Research)

Vivus (NASDAQ:VVUS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Vivus (NASDAQ VVUS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 24.82%

Insider Trading History for Vivus (NASDAQ:VVUS)

Institutional Ownership by Quarter for Vivus (NASDAQ:VVUS)

Vivus (NASDAQ VVUS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2018	Santosh T Varghese	Insider	Sell	390	$0.34	$132.60
1/31/2018	Santosh T Varghese	Insider	Sell	491	$0.43	$211.13	71,805
1/1/2018	Santosh T Varghese	Insider	Sell	444	$0.51	$226.44	72,296
10/3/2017	Santosh T Varghese	Insider	Sell	434	$0.97	$420.98
7/3/2017	Santosh T Varghese	Insider	Sell	423	$1.23	$520.29	73,174
4/4/2017	Santosh T Varghese	Insider	Sell	440	$1.08	$475.20	73,597
3/10/2017	North Tide Capital, Llc	Major Shareholder	Sell	1,149,400	$1.16	$1,333,304.00
3/7/2017	North Tide Capital, Llc	Major Shareholder	Sell	192,800	$1.08	$208,224.00
3/2/2017	North Tide Capital, Llc	Major Shareholder	Sell	160,100	$1.13	$180,913.00
2/27/2017	North Tide Capital, Llc	Major Shareholder	Sell	333,000	$1.14	$379,620.00
2/22/2017	North Tide Capital, Llc	Major Shareholder	Sell	161,800	$1.11	$179,598.00
2/16/2017	North Tide Capital, Llc	Major Shareholder	Sell	305,090	$1.10	$335,599.00
2/13/2017	North Tide Capital, Llc	Major Shareholder	Sell	176,410	$1.11	$195,815.10
2/8/2017	North Tide Capital, Llc	Major Shareholder	Sell	563,527	$1.06	$597,338.62
2/7/2017	North Tide Capital, Llc	Major Shareholder	Sell	6,200	$1.11	$6,882.00
2/6/2017	North Tide Capital, Llc	Major Shareholder	Sell	28,027	$1.10	$30,829.70
2/3/2017	North Tide Capital, Llc	Major Shareholder	Sell	78,633	$1.12	$88,068.96
1/28/2017	Santosh T Varghese	Insider	Sell	429	$1.11	$476.19	74,037
12/31/2016	Santosh T Varghese	Insider	Sell	13,790	$1.12	$15,444.80	74,830
10/1/2016	Santosh T Varghese	Insider	Sell	710	$1.14	$809.40	88,610
8/2/2016	Santosh T Varghese	Insider	Sell	12,559	$1.07	$13,438.13	88,966
7/1/2016	Santosh T Varghese	VP	Sell	366	$1.21	$442.86	101,525
4/7/2016	Santosh T Varghese	Insider	Sell	329	$1.65	$542.85	101,891
4/1/2016	North Tide Capital, Llc	Major Shareholder	Buy	2,160	$1.40	$3,024.00
3/31/2016	North Tide Capital, Llc	Major Shareholder	Buy	383,300	$1.29	$494,457.00
3/28/2016	North Tide Capital, Llc	Major Shareholder	Buy	202,000	$1.12	$226,240.00
3/16/2016	North Tide Capital, Llc	Major Shareholder	Buy	500,000	$1.21	$605,000.00
1/1/2016	John L Slebir	SVP	Sell	2,973	$3.04	$9,037.92	44,555
1/8/2015	North Tide Capital, Llc	Major Shareholder	Buy	500,000	$3.12	$1,560,000.00
1/6/2015	North Tide Capital, Llc	Major Shareholder	Buy	476,800	$3.04	$1,449,472.00
1/2/2015	North Tide Capital, Llc	Major Shareholder	Buy	523,200	$2.90	$1,517,280.00
3/11/2014	Seth H.Z. Fischer	CEO	Buy	3,080	$6.07	$18,695.60	3,080
11/11/2013	Alexander Denner	Director	Buy	566,844	$8.59	$4,869,189.96
9/5/2013	Timothy E Morris	CFO	Sell	10,654	$11.95	$127,315.30
9/4/2013	Michael J Astrue	Director	Buy	10,000	$11.96	$119,600.00
6/27/2013	Jon C Biro	Insider	Buy	2,000	$12.85	$25,700.00
5/29/2013	Ernest Mario	Director	Buy	15,000	$14.68	$220,200.00
8/20/2012	Ernest Mario	Director	Buy	5,000	$20.75	$103,750.00
8/10/2012	Ernest Mario	Director	Buy	20,000	$21.74	$434,800.00

(Data available from 1/1/2013 forward)

Vivus (NASDAQ VVUS) News Headlines

Source:

Date	Headline
	-$0.11 Earnings Per Share Expected for Vivus (VVUS) This Quarter www.americanbankingnews.com - April 17 at 3:06 AM
	Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report? finance.yahoo.com - April 12 at 10:39 AM
	Quotidian Technical Highlights on Selected Biotech Stocks -- Vertex Pharma, VIVUS, Voyager Therapeutics, and ... www.prnewswire.com - April 10 at 4:13 PM
	Vivus (VVUS) Lowered to Strong Sell at ValuEngine www.americanbankingnews.com - April 2 at 10:23 PM
	Zacks: Brokerages Anticipate VIVUS, Inc. (VVUS) to Announce -$0.11 Earnings Per Share www.americanbankingnews.com - March 31 at 8:32 AM
	Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed seekingalpha.com - March 24 at 4:36 PM
	BRIEF-Vivus Reports Qtrly ‍loss Per Share $0.10 www.reuters.com - March 14 at 12:37 PM
	VIVUS (VVUS) Issues Earnings Results www.americanbankingnews.com - March 14 at 12:20 PM
	VIVUS Reports Fourth Quarter 2017 Financial Results finance.yahoo.com - March 13 at 4:28 PM
	Vivus reports 4Q loss finance.yahoo.com - March 13 at 4:28 PM
	VIVUS (VVUS) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - February 27 at 2:34 AM
	Brokerages Expect VIVUS, Inc. (VVUS) to Announce -$0.13 EPS www.americanbankingnews.com - February 25 at 5:20 AM
	Kadmon (KDMN) and VIVUS (VVUS) Critical Analysis www.americanbankingnews.com - February 20 at 4:31 PM
	Head to Head Survey: Transition Therapeutics (TTHI) and VIVUS (VVUS) www.americanbankingnews.com - February 10 at 7:14 PM
	VIVUS (VVUS) Raised to Sell at ValuEngine www.americanbankingnews.com - February 4 at 12:38 PM
	Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPS www.americanbankingnews.com - January 22 at 11:30 AM
	Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS www.bizjournals.com - January 17 at 10:30 AM
	VIVUS (VVUS) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - January 6 at 1:16 PM
	-$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter www.americanbankingnews.com - January 5 at 11:36 AM
	VIVUS (VVUS) Announces Thomas King as Interim CEO - StreetInsider.com www.streetinsider.com - December 27 at 6:16 PM
	ETFs with exposure to VIVUS, Inc. : December 22, 2017 finance.yahoo.com - December 22 at 6:25 PM
	ETFs with exposure to VIVUS, Inc. : December 11, 2017 finance.yahoo.com - December 11 at 4:29 PM
	Pre-Market Technical Scan on Biotech Equities -- Regeneron Pharma, Voyager Therapeutics, Five Prime Therapeutics ... - PR Newswire (press release) www.prnewswire.com - December 5 at 12:20 PM
	VIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngine www.americanbankingnews.com - December 1 at 11:52 PM
	ETFs with exposure to VIVUS, Inc. : November 20, 2017 finance.yahoo.com - November 20 at 4:02 PM
	Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share www.americanbankingnews.com - November 17 at 1:38 PM
	ETFs with exposure to VIVUS, Inc. : November 10, 2017 finance.yahoo.com - November 12 at 1:16 PM
	Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT finance.yahoo.com - November 9 at 9:43 AM
	VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 finance.yahoo.com - November 9 at 9:43 AM
	VIVUS, Inc. (VVUS) Releases Earnings Results, Beats Estimates By $0.07 EPS www.americanbankingnews.com - November 8 at 7:11 PM
	Vivus reports 3Q loss finance.yahoo.com - November 7 at 6:25 PM
	VIVUS Reports Third Quarter 2017 Financial Results feeds.benzinga.com - November 7 at 4:43 PM
	VIVUS, Inc. to Host Earnings Call finance.yahoo.com - November 7 at 1:24 PM
	VIVUS Completes Tacrolimus Pre-IND Meeting With FDA finance.yahoo.com - November 2 at 11:13 AM
	ETFs with exposure to VIVUS, Inc. : October 30, 2017 finance.yahoo.com - October 31 at 12:01 PM
	VIVUS, Inc. (VVUS) Set to Announce Quarterly Earnings on Tuesday www.americanbankingnews.com - October 31 at 8:52 AM
	VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017 feeds.benzinga.com - October 31 at 8:50 AM
	ETFs with exposure to VIVUS, Inc. : October 20, 2017 finance.yahoo.com - October 20 at 4:34 PM
	Financial Review: VIVUS (VVUS) vs. The Competition www.americanbankingnews.com - October 17 at 8:26 AM
	VIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head Review www.americanbankingnews.com - October 12 at 10:32 PM
	ETFs with exposure to VIVUS, Inc. : October 9, 2017 finance.yahoo.com - October 10 at 8:14 AM
	Critical Contrast: VIVUS (VVUS) versus Its Peers www.americanbankingnews.com - October 9 at 6:28 PM
	VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 finance.yahoo.com - October 6 at 12:42 PM
	Argos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head Survey www.americanbankingnews.com - September 29 at 12:34 PM
	Orexigen's (OREX) Contrave Sales Improving on Promotions www.zacks.com - September 28 at 10:20 AM
	Critical Survey: VIVUS (VVUS) versus Its Rivals www.americanbankingnews.com - September 18 at 2:26 AM
	VIVUS, Inc. (VVUS) Sees Large Drop in Short Interest www.americanbankingnews.com - September 15 at 1:28 AM
	VIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH www.streetinsider.com - September 8 at 10:10 AM
	VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis finance.yahoo.com - September 8 at 10:10 AM
	VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension finance.yahoo.com - September 7 at 11:05 AM

Vivus (NASDAQ:VVUS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Vivus (NASDAQ:VVUS) Income Statement, Balance Sheet and Cash Flow Statement

Vivus (NASDAQ VVUS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff